Zealand Pharma

Zealand Pharma announces a transformational, global collaboration and license agreement with Roche to co-develop and co-commercialize our long-acting amylin analog, paving the way to establish it as a future foundational therapy for weight management.  The alliance brings together two companies with a shared vision for addressing the unmet needs of people living with overweight and obesity. We have a mutual aim to unlock the full value of the long-acting amylin analog, redefining the standard of care for people with overweight and obesity. Adam Steensberg, MD, Zealand Pharma CEO, says, “We strongly believe that this amylin analog holds potential as a foundational therapy for weight management, addressing unmet medical needs among the majority of people living with overweight and obesity. We are thrilled to announce this collaboration with Roche, as it is a step forward in realizing this vision.” Join Zealand Pharma’s conference call today, March 12th, at 8:00am ET / 1:00pm CET to learn more #withZEAL

#Obesity is one of the most expansive health challenges globally and contributes to numerous other diseases. We are very pleased to announce today that we have entered into an exclusive collaboration and licensing agreement with Zealand Pharma to join forces in addressing the significant unmet needs of people living with overweight and obesity #PartneringforInnovation #RochePartnering Read more: https://lnkd.in/dxPyJJq9

Today on World Obesity Day, we acknowledge one of the greatest healthcare challenges of our time. Obesity is a disease associated with more than 220 complications and comorbidities, including cardiovascular disease, liver disease, type 2 diabetes, kidney disease, and neuro-inflammation.   According to the NCD Risk Factor Collaboration (NCD-Ris-C), it is estimated that, in 2024, more than 1 billion people across the globe are now living with obesity. That is nearly 880 million adults and 159 million children and adolescents aged 5 – 19 years (1). Today is an important day to take the time to not only understand obesity as a disease, but how we can work together to address its root causes, have a real impact on society, and recognize obesity as a complex disease profoundly impacting public health.   Access even more information on obesity and how you can play a role in making a change via the World Obesity Federation #worldobesityday   1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627‐2642. doi:10.1016/S0140-6736(17)32129-3

Last Friday for Rare Disease Day, Zealanders marked the day by wearing stripes. Every year, we ask our team to #ShowYourStripes to support the 300 million people worldwide living with rare diseases. Why stripes? "When you hear hoofbeats, think horses not zebras." This is a phrase that medical professionals are often taught as a reminder to look for more common diagnoses. In other words, when they “hear hoofbeats”, they should first look for a horse – not a zebra. Rare diseases are the zebras among the horses. Thank you to everyone on our team that joined in person and virtually to learn about and support the rare disease community. #withZEAL National Organization for Rare Disorders EURORDIS-Rare Diseases Europe

🦓 February 28th, 2025 🦓 marks the 18th annual Rare Disease Day – a day to increase awareness and to promote working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease. While rare diseases are just that – rare – they are probably closer to you than you think with 1 in 17 people worldwide living with a rare disease. These diseases have a broad impact, effecting not only the people living with them, but their families, friends, and caregivers. At Zealand Pharma, we have a long-standing commitment to helping change the lives of people living with certain rare diseases. #withZEAL #rarediseaseday Join Zealand Pharma and thousands of others worldwide by wearing stripes and visiting the Rare Disease Day website: https://lnkd.in/gk6hbAF to educate yourself and learn more about what it means to live with a rare disease and how you can support those affected! National Organization for Rare Disorders EURORDIS-Rare Diseases Europe

“Looking at our full year results, I can confidently say we had a transformational 2024 at Zealand Pharma.” – Adam Steensberg, CEO   Our annual report for 2024 shows how, over the last year, we have built a solid foundation for Zealand Pharma to enter its next phase of growth. This foundation stands on more than 26 years of peptide innovation and, in 2024, was furthered strengthened by our differentiated pipeline, increased financial position, and, most importantly, the addition of 118 Zealanders to our team. Learn more about Zealand Pharma’s 2024 achievements in this year’s annual report here: https://lnkd.in/dvWQuMwH   #withZeal #AnnualReport

Native peptides have powerful biological functions. But native peptide hormones are unstable and must be modified when we want to use them in medicine. Despite these challenges, Zealand Pharma is dedicated to working with peptides, but why? Check out the slides below to learn more about the challenges (and advantages!) of peptides. ⬇️⬇️⬇️   Learn more about peptides on our website: https://lnkd.in/dr23y3iz #peptides #biotech #withZeal

“It’s the small but important things that make me proud to work here because it takes everyone’s effort to run a company like this and I feel that at Zealand we all contribute.” 🤝 For 26 years, Margit Andersen has made peptides at Zealand Pharma.   Margit was one of the very first people to join Zealand and, as a laboratory technician, is one of the first links in the chain that works to create new medicines for people who need them. In addition to her lab work, one of the main reasons you still find Margit at Zealand is her colleagues. “My favorite thing about Zealand is my colleagues and the way we trust each other. That creates a culture where almost everyone can work in the way that suits them best.” Read more of Margit’s story on our website: https://lnkd.in/dUenWH-x   Are you interested in playing a role in Zealand’s journey? Explore our open positions: https://lnkd.in/dwhFQWzp #withZEAL

Did you miss Zealand Pharma CEO Adam Steensberg's presentation at the J.P. Morgan Healthcare Conference this week? If so, we’ve got you covered. Follow this link to access the webcast audio recording from Monday via our website: https://lnkd.in/dgYjqKb7 In his presentation, Adam discusses Zealand Pharma, who we are as a company, our disease focus areas, and more. 

We are delighted to share that Steven R. Smith, MD, has joined Zealand Pharma. As Senior Global Medical Advisor in Obesity, Steven will support Zealand’s obesity research and clinical development programs. ⬇️ Steven brings with him 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications. As a recognized leader in obesity and metabolism research, Steven will play a central role as we advance our innovative peptide-based assets for the treatment of obesity and related health conditions. Learn more about Steven and his role in the press release: #withZEAL